Nong Xu

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

F. Wang, Xiaoli Wei, Fenggong Wang et al. · Annals of Oncology · 2019 · 476 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Mast Cells, Histamine, and IL-6 Regulate the Selective Influx of Dendritic Cell Subsets into an Inflamed Lymph Node

Wojciech Dawicki, Nong Xu, Jean S. Marshall · The Journal of Immunology · 2010 · 104 citations · Full text

Life Sciences, Immunology, Pathology +15

Celastrol induces apoptosis in non-small-cell lung cancer A549 cells through activation of mitochondria- and Fas/FasL-mediated pathways

Haibo Mou, Yi Zheng, Peng Zhao et al. · Toxicology in Vitro · 2011 · 100 citations

Life Sciences, Cell Biology, Oncology +13

Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors

Qiong Zhao, Jianzhong Shentu, Nong Xu et al. · Lung Cancer · 2010 · 98 citations

Medicine, Oncology, Pharmacology +12

Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial

Haiping Jiang, Yulong Zheng, Jiong Qian et al. · BMC Cancer · 2020 · 62 citations · Full text

Medicine, Oncology, Pharmacology +17